accessibility menu, dialog, popup

UserName
Viewing profile as user:

Acyl bromides

Organic compounds that contain an acyl group bonded to a bromide ion; an acyl group is a carbon atom bonded to an alkyl functional group, and an oxygen atom via a double bond.

Filtered Search Results

Products from some of our suppliers do not display in filtered search results. Please clear all filters to see these products.

Narrow Results

Narrow Results

category

brands

  • (3)

special interests

  • (3)

Search Within Results
Keyword Search:
1 – 3 of 3 results
1

Medchemexpress LLC Thonzonium bromide | 553-08-2 | 99.86% | 1 ML
SDP

Thonzonium bromide is an antibacterial agent and monocationic surface-active agent that inhibits RANKL-induced osteoclast formation and bone resorption in vitro. It prevents LPS-induced bone loss in vivo by blocking RANKL-induced activation of NF-κB, ERK, c-Fos, and NFATc1, which are crucial for osteoclast formation. Additionally, it disrupts F-actin ring formation in mature osteoclasts and inhibits proton transport in a dose-dependent manner.

  • Inhibits RANKL-induced osteoclast formation
  • Prevents LPS-induced bone loss in vivo
  • Blocks key signaling pathways for osteoclast formation
  • Disrupts F-actin ring formation in mature osteoclasts
  • Inhibits proton transport

ENCOMPASS_PREFERRED
2

Medchemexpress LLC 1-Hexadecanaminium, N-[2-[[(4-methoxyphenyl)methyl]-2-pyrimidinylamino]ethyl]-N,N-dimethyl-, bromide (1:1) | 553-08-2 | 99.9% | 100 MG
SDP

Thonzonium bromide is an antibacterial agent and a monocationic surface-active agent. It inhibits RANKL-induced osteoclast formation and bone resorption in vitro, and prevents LPS-induced bone loss in vivo. This compound also inhibits proton transport in a dose-dependent manner (EC50=69 μM).

  • Antibacterial agent.
  • Monocationic surface-active agent.
  • Inhibits RANKL-induced osteoclast formation and bone resorption in vitro.
  • Prevents LPS-induced bone loss in vivo.
  • Inhibits proton transport in a dose-dependent manner (EC50=69 μM).
  • Blocks RANKL-induced activation of NF-κB, ERK, and c-Fos, as well as NFATc1 induction.
  • Disrupts F-actin ring formation, causing disturbances in cytoskeletal structure in mature osteoclasts during bone resorption.
  • Exhibits protective effects in an in vivo murine model of LPS-induced calvarial osteolysis.

ENCOMPASS_PREFERRED
3

Medchemexpress LLC 1-Hexadecanaminium, N-[2-[[(4-methoxyphenyl)methyl]-2-pyrimidinylamino]ethyl]dimethyl bromide | 553-08-2 | 99.9% | 5 MG
SDP

Thonzonium bromide is an antibacterial and monocationic surface-active agent. It inhibits RANKL-induced osteoclast formation and bone resorption in vitro, preventing LPS-induced bone loss in vivo. It also inhibits proton transport in a dose-dependent manner, blocking the activation of NF-κB, ERK, and c-Fos, and the induction of NFATc1. This compound disrupts F-actin ring formation in mature osteoclasts, and has shown protective effects in a murine model of LPS-induced calvarial osteolysis.

  • Antibacterial agent
  • Monocationic surface-active agent
  • Inhibits RANKL-induced osteoclast formation and bone resorption in vitro
  • Prevents LPS-induced bone loss in vivo
  • Inhibits proton transport
  • Blocks RANKL-induced activation of NF-κB, ERK, and c-Fos
  • Disrupts F-actin ring formation
  • Activates human PXR in HepG2 cells

ENCOMPASS_PREFERRED